A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 486,800 shares of MRSN stock, worth $778,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares
486,800
Previous 719,300 32.32%
Holding current value
$778,880
Previous $1.45 Million 36.33%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.23 - $2.25 $285,975 - $523,125
-232,500 Reduced 32.32%
486,800 $920,000
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $1.13 Million - $2.51 Million
563,500 Added 361.68%
719,300 $1.45 Million
Q1 2024

May 15, 2024

BUY
$2.16 - $5.94 $9,504 - $26,136
4,400 Added 2.91%
155,800 $697,000
Q4 2023

Feb 14, 2024

SELL
$1.11 - $2.34 $232,323 - $489,761
-209,300 Reduced 58.03%
151,400 $351,000
Q3 2023

Nov 14, 2023

SELL
$1.06 - $3.91 $230,444 - $850,034
-217,400 Reduced 37.61%
360,700 $458,000
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $697,312 - $2.16 Million
-226,400 Reduced 28.14%
578,100 $1.9 Million
Q1 2023

May 15, 2023

SELL
$4.0 - $7.02 $995,200 - $1.75 Million
-248,800 Reduced 23.62%
804,500 $3.31 Million
Q4 2022

Feb 14, 2023

SELL
$5.65 - $7.86 $363,860 - $506,184
-64,400 Reduced 5.76%
1,053,300 $6.17 Million
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $143,530 - $248,000
31,000 Added 2.85%
1,117,700 $7.56 Million
Q2 2022

Aug 15, 2022

SELL
$2.84 - $5.0 $746,352 - $1.31 Million
-262,800 Reduced 19.47%
1,086,700 $5.02 Million
Q1 2022

May 16, 2022

BUY
$3.74 - $6.63 $1.12 Million - $1.98 Million
299,300 Added 28.5%
1,349,500 $5.39 Million
Q4 2021

Feb 14, 2022

BUY
$5.48 - $9.86 $2.3 Million - $4.14 Million
420,200 Added 66.7%
1,050,200 $6.53 Million
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $534,144 - $902,928
62,400 Added 10.99%
630,000 $5.94 Million
Q2 2021

Aug 16, 2021

SELL
$13.28 - $18.07 $253,648 - $345,137
-19,100 Reduced 3.26%
567,600 $7.71 Million
Q1 2021

May 17, 2021

BUY
$15.31 - $26.52 $1.48 Million - $2.57 Million
96,800 Added 19.76%
586,700 $9.49 Million
Q4 2020

Feb 16, 2021

BUY
$16.84 - $27.59 $3.29 Million - $5.39 Million
195,400 Added 66.35%
489,900 $13 Million
Q3 2020

Nov 16, 2020

BUY
$16.2 - $25.7 $2.8 Million - $4.44 Million
172,900 Added 142.19%
294,500 $5.48 Million
Q2 2020

Aug 14, 2020

BUY
$5.24 - $23.4 $367,324 - $1.64 Million
70,100 Added 136.12%
121,600 $2.85 Million
Q1 2020

May 15, 2020

BUY
$4.41 - $9.28 $62,181 - $130,847
14,100 Added 37.7%
51,500 $300,000
Q4 2019

Feb 14, 2020

BUY
$1.45 - $6.73 $2,175 - $10,095
1,500 Added 4.18%
37,400 $214,000
Q3 2019

Nov 14, 2019

BUY
$1.54 - $4.2 $37,576 - $102,480
24,400 Added 212.17%
35,900 $57,000
Q2 2019

Aug 14, 2019

BUY
$3.84 - $6.4 $44,160 - $73,600
11,500 New
11,500 $47,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $155M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.